Seikagaku Corporation

Headquartered in Tokyo, Japan, Seikagaku Corporation, established in 1947, specializes in the global development, manufacturing, and distribution of pharmaceuticals and medical devices, with a core focus on glycoconjugates. The company, which was formerly known as K.K. Seikagaku Kenkyusho until its name change in 1962, operates through two primary segments: Pharmaceuticals and LAL. Its product portfolio encompasses a range of therapeutic and surgical solutions. For joint health, Seikagaku provides intra-articular injections like ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX, designed to enhance joint function. The company also supplies ophthalmic surgical aids such as OPEGAN, OPEGAN Hi, and SHELLGAN, alongside MucoUp for endoscopic mucosal resection. Other notable offerings include Gel-One, a cross-linked hyaluronate hydrogel addressing knee osteoarthritis, and HERNICORE for lumbar disc herniation. Beyond finished products, Seikagaku is a supplier of bulk materials, specifically sodium hyaluronate and sodium chondroitin sulfate, which find application in various pharmaceutical and cosmetic formulations. Furthermore, the company develops and markets specialized endotoxin-detecting reagents, including Pyrochrome, ENDOSPECY, and TOXICOLOR, which are crucial for quality assurance in injectable pharmaceuticals, biological products, medical devices, manufacturing operations, and dialysate water quality. Its offerings also extend to oral care, featuring the KINUSUI Spray mouthwash. Seikagaku maintains a robust development pipeline, with promising candidates such as SI-6603 for lumbar disc herniation, SI-614 (a modified hyaluronate for dry eyes), SI-613 for osteoarthritis, SI-613-ETP targeting enthesopathy, and SI-449, a powdered adhesion barrier.